CopyMark Law Group
4.9/5
Drawing for TIDES WUXI TIDES

USPTO serial 97909703

TIDES WUXI TIDES

Reviewed by CopyMark Law Group

Reg. 7874587Status 700Registered
Filing date
Status date
Registration date
Jul 29, 2025
Examiner
KETCHUM, BRENDAN J
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with TIDES WUXI TIDES?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jonathan M. Rixen

Jonathan M. Rixen Dennemeyer & Associates, LLC230 W. Monroe St.Suite 2100Chicago, IL 60606

Goods and services

ClassDescriptionStatusFirst use
005Prescription and non-prescription medicines, namely, pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Medicines for human purposes, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Raw material medicine, namely, medicines for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Pharmaceutical preparations, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; pharmaceutical preparations, namely, antivirals; Chemico-pharmaceutical preparations for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases; Biological preparations for medical purposes for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases; Chemical preparations for the diagnosis of pregnancy; Chemical preparations for pharmaceutical or medical purposes, for the treatment of cancer, cardiovascular, hematologic, neurological, gastrointestinal and genetic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, coagulation disorders, infectious and parasitic diseases, neoplasms, diseases of the blood and blood-forming organs, endocrine, nutritional and metabolic diseases, mental, behavioral and neurodevelopmental disorders, sleep-wake disorders, diseases of the nervous system, diseases of the respiratory system, diseases of the digestive system, diseases of the skin; Chemical preparations for medical purposes, namely, chemical reagents for medical purposes; Chemical preparations for medical purposes; Diagnostic preparations for medical purposes; Nutritional supplements; Drugs for medical purposes; Reagent paper for medical purposes; Medical reagents; Disinfectants for hygiene purposes; Cultures of microorganisms for medical use; Biomedicine; Adjuvants for medical purposes; Vaccines; Veterinary preparationsACTIVEApr 17, 2023
040Metal treating; Material treatment information; Processing and handling of chemical reagents, namely, treatment of materials in the nature of chemicals; Cloth treating; Paper treating; Processing of oil; Stripping finishes, namely, treatment of wood for preservation purposes; Recycling of waste and trash; Air purification; Processing of medicinal materials being material treatment services in connection with recycling; Cryopreservation services; Providing information relating to material treatment; Custom assembling of materials for others being custom manufacture of pharmaceuticals, chemotherapy drugs, antibiotic medicines, and vaccines by pharmaceutical compounders; Processing of biomedical materials for others being biomanufacturing for others in the nature of manufacturing of pharmaceuticals and vaccines using biological organisms in the manufacturing process; Customized production service being custom manufacturing of pharmaceuticals; Custom manufacture of pharmaceuticals medical preparationACTIVEApr 17, 2023
042Computer programming; Material testing; Technical research in the field of pharmaceutical studies; Research and development of new products for others; Technology consultancy in the field of cybersecurity; Chemical analysis; Chemistry services, namely, chemistry consultation; Chemical research; Biological research; conducting clinical trials for others, being for scientific and medical research; Quality checking and testing, namely, quality control for others; Scientific laboratory services; Genome structure and function analysis; Gene screening, namely, DNA screening for scientific research purpose; Biomedical research services; Stem cell research service; Drug research and development services, namely, pharmaceutical research; cell culture services for scientific research purposes, for others; Design and development of computer hardware and software; Development and creation of computer programs for data processing; Computer programming in the field of medical treatment; Product quality testing; assessment of quality of products; Scientific research; Surveying; Bacteriological research; The design, production in the nature of design, or maintenance of a computer program; Computer software design; Computer technology consultancy in the field of engineering; Information technology consulting relating to computer network design; Artificial intelligence technology consulting; Research on artificial intelligence technology; Research and development of new products; Pharmaceutical research services; Development of pharmaceutical preparations and medicines; Drug evaluation, namely, pharmaceutical product evaluation; Vaccine research and development services; Cancer medicine research; Biotechnology research; Drug testing being testing of pharmaceuticals; Pharmaceutical research; Cancer scientific research for medical purposes; Development and Testing of Chemical production methods; Implementation of early evaluation in the field of new drugs, namely, product quality testing; Biochemical research and analysis; Chemical analysis evaluation service; Chemical synthesis evaluation service; scientific research of the mode of action of chemical combinations on animalsACTIVEApr 17, 2023

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 29, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jul 29, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 16, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Jul 10, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Jun 9, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Jan 22, 2025EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jan 22, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 22, 2025EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Jan 22, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 22, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 4, 2024EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Apr 30, 2024IUAFUSE AMENDMENT FILED—
Apr 30, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 5, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 5, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 14, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 14, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 26, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 9, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 8, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 8, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 5, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 5, 2024ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Jan 5, 2024EWORTEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED—
Jan 5, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 5, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jan 5, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Jan 5, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Nov 7, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 7, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 7, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 28, 2023DOCKASSIGNED TO EXAMINER—
May 26, 2023MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
May 25, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 1, 2023NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance